Mycronic AB (publ) Logo

Mycronic AB (publ)

MYCR.ST

(2.8)
Stock Price

396,60 SEK

22.82% ROA

27.84% ROE

24.24x PER

Market Cap.

36.130.557.480,00 SEK

3.8% DER

1.22% Yield

23.08% NPM

Mycronic AB (publ) Stock Analysis

Mycronic AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Mycronic AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (15.58%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (5%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

5 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (1.726) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's elevated P/BV ratio (4.96x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

10 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

Mycronic AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Mycronic AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Mycronic AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Mycronic AB (publ) Revenue
Year Revenue Growth
2002 496.050.000
2003 427.959.000 -15.91%
2004 839.481.000 49.02%
2005 1.275.759.000 34.2%
2006 1.204.143.000 -5.95%
2007 522.981.000 -130.25%
2008 568.617.000 8.03%
2009 828.896.000 31.4%
2010 1.287.782.000 35.63%
2011 1.197.580.000 -7.53%
2012 1.353.927.000 11.55%
2013 996.988.000 -35.8%
2014 1.475.004.000 32.41%
2015 1.814.960.000 18.73%
2016 2.319.254.000 21.74%
2017 3.001.159.000 22.72%
2018 3.780.586.000 20.62%
2019 4.307.000.000 12.22%
2020 3.882.000.000 -10.95%
2021 4.635.000.000 16.25%
2022 5.119.000.000 9.45%
2023 5.096.000.000 -0.45%
2023 5.706.000.000 10.69%
2024 6.108.000.000 6.58%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Mycronic AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2002 185.156.000
2003 123.541.000 -49.87%
2004 176.429.000 29.98%
2005 310.937.000 43.26%
2006 318.487.000 2.37%
2007 279.004.000 -14.15%
2008 149.644.000 -86.45%
2009 251.409.000 40.48%
2010 318.121.000 20.97%
2011 288.997.000 -10.08%
2012 289.967.000 0.33%
2013 183.373.000 -58.13%
2014 197.684.000 7.24%
2015 266.723.000 25.88%
2016 348.406.000 23.44%
2017 347.995.000 -0.12%
2018 455.999.000 23.69%
2019 559.000.000 18.43%
2020 514.000.000 -8.75%
2021 548.000.000 6.2%
2022 638.000.000 14.11%
2023 632.000.000 -0.95%
2023 653.000.000 3.22%
2024 728.000.000 10.3%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Mycronic AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 78.436.000
2003 67.232.000 -16.66%
2004 69.733.000 3.59%
2005 70.400.000 0.95%
2006 -31.051.000 326.72%
2007 54.632.000 156.84%
2008 96.382.000 43.32%
2009 112.553.000 14.37%
2010 119.751.000 6.01%
2011 426.192.000 71.9%
2012 78.774.000 -441.03%
2013 78.885.000 0.14%
2014 89.956.000 12.31%
2015 91.114.000 1.27%
2016 137.846.000 33.9%
2017 181.414.000 24.02%
2018 228.108.000 20.47%
2019 237.000.000 3.75%
2020 16.000.000 -1381.25%
2021 18.000.000 11.11%
2022 32.000.000 43.75%
2023 288.000.000 88.89%
2023 338.000.000 14.79%
2024 376.000.000 10.11%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Mycronic AB (publ) EBITDA
Year EBITDA Growth
2002 -39.203.000
2003 -126.034.000 68.89%
2004 219.167.000 157.51%
2005 364.637.000 39.89%
2006 338.946.000 -7.58%
2007 -82.681.000 509.94%
2008 98.550.000 183.9%
2009 -23.890.000 512.52%
2010 172.545.000 113.85%
2011 22.678.000 -660.85%
2012 102.430.000 77.86%
2013 64.117.000 -59.75%
2014 302.863.000 78.83%
2015 566.167.000 46.51%
2016 724.107.000 21.81%
2017 923.547.000 21.6%
2018 1.096.505.000 15.77%
2019 1.315.000.000 16.62%
2020 1.118.000.000 -17.62%
2021 1.265.000.000 11.62%
2022 1.156.000.000 -9.43%
2023 1.052.000.000 -9.89%
2023 1.388.000.000 24.21%
2024 1.436.000.000 3.34%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Mycronic AB (publ) Gross Profit
Year Gross Profit Growth
2002 236.853.000
2003 164.494.000 -43.99%
2004 469.420.000 64.96%
2005 694.335.000 32.39%
2006 654.115.000 -6.15%
2007 153.241.000 -326.85%
2008 161.463.000 5.09%
2009 327.498.000 50.7%
2010 633.115.000 48.27%
2011 488.035.000 -29.73%
2012 611.907.000 20.24%
2013 446.306.000 -37.1%
2014 711.699.000 37.29%
2015 1.075.576.000 33.83%
2016 1.410.228.000 23.73%
2017 1.720.619.000 18.04%
2018 2.097.529.000 17.97%
2019 2.399.000.000 12.57%
2020 2.080.000.000 -15.34%
2021 2.284.000.000 8.93%
2022 2.288.000.000 0.17%
2023 2.496.000.000 8.33%
2023 2.856.000.000 12.61%
2024 3.132.000.000 8.81%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Mycronic AB (publ) Net Profit
Year Net Profit Growth
2002 -63.378.000
2003 -158.666.000 60.06%
2004 109.839.000 244.45%
2005 117.430.000 6.46%
2006 92.902.000 -26.4%
2007 -207.541.000 144.76%
2008 30.645.000 777.24%
2009 -144.093.000 121.27%
2010 36.766.000 491.92%
2011 -88.830.000 141.39%
2012 -43.972.000 -102.01%
2013 13.745.000 419.91%
2014 266.245.000 94.84%
2015 442.475.000 39.83%
2016 526.303.000 15.93%
2017 626.259.000 15.96%
2018 789.539.000 20.68%
2019 855.000.000 7.66%
2020 694.000.000 -23.2%
2021 828.000.000 16.18%
2022 741.000.000 -11.74%
2023 820.000.000 9.63%
2023 998.000.000 17.84%
2024 1.148.000.000 13.07%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Mycronic AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -3
2003 -5 50%
2004 2 300%
2005 2 0%
2006 2 -100%
2007 -4 125%
2008 -1 0%
2009 -2 100%
2010 0 0%
2011 -1 0%
2012 0 0%
2013 0 0%
2014 3 100%
2015 5 50%
2016 5 20%
2017 6 16.67%
2018 8 25%
2019 9 0%
2020 7 -14.29%
2021 8 12.5%
2022 8 -14.29%
2023 8 12.5%
2023 10 20%
2024 12 9.09%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Mycronic AB (publ) Free Cashflow
Year Free Cashflow Growth
2002 -276.294.000
2003 -56.922.000 -385.39%
2004 -148.600.000 61.69%
2005 283.185.000 152.47%
2006 122.516.000 -131.14%
2007 -121.774.000 200.61%
2008 22.606.000 638.68%
2009 74.194.000 69.53%
2010 81.356.000 8.8%
2011 -49.148.000 265.53%
2012 61.335.000 180.13%
2013 -84.225.000 172.82%
2014 399.036.000 121.11%
2015 635.684.000 37.23%
2016 419.141.000 -51.66%
2017 933.880.000 55.12%
2018 633.606.000 -47.39%
2019 393.000.000 -61.22%
2020 991.000.000 60.34%
2021 908.000.000 -9.14%
2022 712.000.000 -27.53%
2023 212.000.000 -235.85%
2023 1.414.000.000 85.01%
2024 350.000.000 -304%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Mycronic AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2002 -96.962.000
2003 169.910.000 157.07%
2004 -11.045.000 1638.34%
2005 323.500.000 103.41%
2006 218.978.000 -47.73%
2007 -77.256.000 383.44%
2008 105.803.000 173.02%
2009 81.576.000 -29.7%
2010 120.936.000 32.55%
2011 -15.424.000 884.08%
2012 69.939.000 122.05%
2013 -47.222.000 248.11%
2014 417.597.000 111.31%
2015 661.421.000 36.86%
2016 461.854.000 -43.21%
2017 983.755.000 53.05%
2018 702.370.000 -40.06%
2019 545.000.000 -28.88%
2020 1.126.000.000 51.6%
2021 998.000.000 -12.83%
2022 853.000.000 -17%
2023 212.000.000 -302.36%
2023 1.608.000.000 86.82%
2024 382.000.000 -320.94%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Mycronic AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2002 179.332.000
2003 226.832.000 20.94%
2004 137.555.000 -64.9%
2005 40.315.000 -241.2%
2006 96.462.000 58.21%
2007 44.518.000 -116.68%
2008 83.197.000 46.49%
2009 7.382.000 -1027.03%
2010 39.580.000 81.35%
2011 33.724.000 -17.36%
2012 8.604.000 -291.96%
2013 37.003.000 76.75%
2014 18.561.000 -99.36%
2015 25.737.000 27.88%
2016 42.713.000 39.74%
2017 49.875.000 14.36%
2018 68.764.000 27.47%
2019 152.000.000 54.76%
2020 135.000.000 -12.59%
2021 90.000.000 -50%
2022 141.000.000 36.17%
2023 0 0%
2023 194.000.000 100%
2024 32.000.000 -506.25%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Mycronic AB (publ) Equity
Year Equity Growth
2002 631.353.000
2003 798.444.000 20.93%
2004 907.998.000 12.07%
2005 1.025.252.000 11.44%
2006 1.109.846.000 7.62%
2007 907.464.000 -22.3%
2008 888.576.000 -2.13%
2009 1.047.154.000 15.14%
2010 1.314.722.000 20.35%
2011 1.231.699.000 -6.74%
2012 1.168.286.000 -5.43%
2013 1.165.432.000 -0.24%
2014 1.207.097.000 3.45%
2015 1.268.230.000 4.82%
2016 1.411.611.000 10.16%
2017 1.800.345.000 21.59%
2018 2.378.962.000 24.32%
2019 2.978.000.000 20.12%
2020 3.378.000.000 11.84%
2021 3.997.000.000 15.49%
2022 4.703.000.000 15.01%
2023 4.778.000.000 1.57%
2023 5.283.000.000 9.56%
2024 5.642.000.000 6.36%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Mycronic AB (publ) Assets
Year Assets Growth
2002 1.276.390.000
2003 1.640.586.000 22.2%
2004 1.571.849.000 -4.37%
2005 1.870.845.000 15.98%
2006 1.709.731.000 -9.42%
2007 1.506.663.000 -13.48%
2008 1.376.427.000 -9.46%
2009 1.408.422.000 2.27%
2010 1.713.797.000 17.82%
2011 1.586.714.000 -8.01%
2012 1.472.054.000 -7.79%
2013 1.401.481.000 -5.04%
2014 1.599.756.000 12.39%
2015 1.742.221.000 8.18%
2016 2.755.255.000 36.77%
2017 3.238.682.000 14.93%
2018 4.199.310.000 22.88%
2019 4.800.000.000 12.51%
2020 5.319.000.000 9.76%
2021 6.136.000.000 13.31%
2022 7.340.000.000 16.4%
2023 7.851.000.000 6.51%
2023 8.340.000.000 5.86%
2024 9.085.000.000 8.2%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Mycronic AB (publ) Liabilities
Year Liabilities Growth
2002 645.037.000
2003 842.142.000 23.41%
2004 663.851.000 -26.86%
2005 845.593.000 21.49%
2006 599.885.000 -40.96%
2007 599.199.000 -0.11%
2008 487.851.000 -22.82%
2009 361.268.000 -35.04%
2010 399.075.000 9.47%
2011 355.015.000 -12.41%
2012 303.768.000 -16.87%
2013 236.049.000 -28.69%
2014 392.659.000 39.88%
2015 473.991.000 17.16%
2016 1.343.644.000 64.72%
2017 1.438.337.000 6.58%
2018 1.820.348.000 20.99%
2019 1.822.000.000 0.09%
2020 1.941.000.000 6.13%
2021 2.139.000.000 9.26%
2022 2.637.000.000 18.89%
2023 3.033.000.000 13.06%
2023 3.057.000.000 0.79%
2024 3.443.000.000 11.21%

Mycronic AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
66.19
Net Income per Share
15.27
Price to Earning Ratio
24.24x
Price To Sales Ratio
5.59x
POCF Ratio
19.09
PFCF Ratio
20.34
Price to Book Ratio
6.45
EV to Sales
5.22
EV Over EBITDA
17.54
EV to Operating CashFlow
17.82
EV to FreeCashFlow
18.99
Earnings Yield
0.04
FreeCashFlow Yield
0.05
Market Cap
36,13 Bil.
Enterprise Value
33,73 Bil.
Graham Number
140.47
Graham NetNet
7.99

Income Statement Metrics

Net Income per Share
15.27
Income Quality
1.22
ROE
0.28
Return On Assets
0.16
Return On Capital Employed
0.29
Net Income per EBT
0.79
EBT Per Ebit
1.03
Ebit per Revenue
0.28
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.06
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.53
Operating Profit Margin
0.28
Pretax Profit Margin
0.29
Net Profit Margin
0.23

Dividends

Dividend Yield
0.01
Dividend Yield %
1.22
Payout Ratio
0
Dividend Per Share
4.5

Operating Metrics

Operating Cashflow per Share
19.39
Free CashFlow per Share
18.19
Capex to Operating CashFlow
0.06
Capex to Revenue
0.02
Capex to Depreciation
1.41
Return on Invested Capital
0.25
Return on Tangible Assets
0.23
Days Sales Outstanding
54.18
Days Payables Outstanding
67.09
Days of Inventory on Hand
233.72
Receivables Turnover
6.74
Payables Turnover
5.44
Inventory Turnover
1.56
Capex per Share
1.2

Balance Sheet

Cash per Share
25,97
Book Value per Share
57,80
Tangible Book Value per Share
31.66
Shareholders Equity per Share
57.42
Interest Debt per Share
2.18
Debt to Equity
0.04
Debt to Assets
0.02
Net Debt to EBITDA
-1.25
Current Ratio
2.01
Tangible Asset Value
3,09 Bil.
Net Current Asset Value
2,31 Bil.
Invested Capital
5971000000
Working Capital
2,89 Bil.
Intangibles to Total Assets
0.28
Average Receivables
1,13 Bil.
Average Payables
0,50 Bil.
Average Inventory
1851000000
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Mycronic AB (publ) Dividends
Year Dividends Growth
2014 5
2015 3 -66.67%
2016 3 -50%
2017 2 0%
2018 3 0%
2019 3 33.33%
2020 4 25%
2021 3 -33.33%
2022 3 0%
2023 4 0%
2024 5 25%

Mycronic AB (publ) Profile

About Mycronic AB (publ)

Mycronic AB (publ), together with its subsidiaries, develops, manufactures, and sells production equipment for electronics industry in Sweden, rest of Europe, the United States, other Americas, China, South Korea, rest of Asia, and internationally. The company operates through four segments: Pattern Generators, High Flex, High Volume, and Global Technologies. The Pattern Generators segment develops, manufactures, and markets mask writers and measuring machines for production of advanced photomasks for manufacturing of screens for TVs, cars, mobile phones, tablets, and computers, as well as the semiconductor components. The High Flex segment develops, manufactures, and markets surface mount technology (SMT) and inspection equipment for flexible printed circuit board (PCBs) assembly. This segment offers MYPro Line, which integrates advanced jet printing and dispensing, pick-and-place, advanced process control solutions, and 3D inspection systems; MYTower material handling systems; and MYSmart dispensing and coating solutions. The High Volume segment develops, manufactures, and markets equipment for dispensing and conformal coating of circuit boards for manufacturers of mobile phones, tablets, computers, and electronics for electric vehicles, as well as automated screen printers. The Global Technologies segment offers die-bonding services for microelectronics and optoelectronic applications; advanced electrical measurement of bare board PCBs and substrates; flying probe test system, an automated electrical measurement system for low to mid quantities and complex boards; and grid test systems for volume bare board verification. It sells its products through agents and distributors. The company serves industrial, aerospace, defense, automotive, energy, medical, and telecom sectors. The company was formerly known as Micronic Mydata AB (publ) and changed its name to Mycronic AB (publ) in June 2014. Mycronic AB (publ) is headquartered in Täby, Sweden.

CEO
Mr. Anders Lindqvist
Employee
2.027
Address
Nytorpsvägen
Täby, 183 03

Mycronic AB (publ) Executives & BODs

Mycronic AB (publ) Executives & BODs
# Name Age
1 Mr. Clemens G. Jargon
Senior Vice President of High Flex Division
70
2 Mikael Wahlsten
Head of Product Strategy & Development
70
3 Ms. Lena Bavegard M.Sc. (Eng.)
Senior Vice President of Global Functions
70
4 Ms. Johanna Jarl
Senior Vice President of People & Culture
70
5 Mr. Sven Chetkovich
Director of Investor Relations
70
6 Mr. Anders Lindqvist
President & Chief Executive Officer
70
7 Mr. Magnus Marthinsson
Senior Vice President of Global Technologies
70
8 Ms. Charlott Samuelsson
Senior Vice President of Pattern Generators Division
70
9 Mr. Anders Rudolfsson
Senior Equity Sales
70
10 Mr. Pierre Brorsson BA, MSc.
Chief Financial Officer & Senior Vice President of Corporate Development
70

Mycronic AB (publ) Competitors

Nolato AB (publ) Logo
Nolato AB (publ)

NOLA-B.ST

(2.0)
Vitrolife AB (publ) Logo
Vitrolife AB (publ)

VITR.ST

(3.2)
Bure Equity AB (publ) Logo
Bure Equity AB (publ)

BURE.ST

(2.5)
Sectra AB (publ) Logo
Sectra AB (publ)

SECT-B.ST

(3.0)